

## **Report from Gambro's Annual General Meeting, April 10, 2003**

Stockholm, Sweden, April 11, 2003 – Gambro AB (Stockholmsbörsen: GAMBaST, GAMBbST), a leading international medical technology and healthcare company, reports the following decisions taken at the Annual General Meeting.

### **Board of Directors**

Claes Dahlbäck, Sandra Austin Crayton, Wilbur H Gantz, Peter H Grassmann, Juha P Kokko, Sören Mellstig and Håkan Mogren were reelected members of the Board. Lena Torell was elected new member of the Board. At the statutory Board meeting following the Annual General Meeting, Claes Dahlbäck was elected Chairman and Håkan Mogren was elected Vice Chairman.

In accordance with the company's policy, Gösta Gahrton was not available for reelection, as he has reached retirement age. Björn Svedberg had declined to be reelected.

### **Dividend**

The Meeting approved a dividend for 2002 of SEK 1.10 per share, with a record date of April 15, 2003. With this record date, dividends are expected to be paid from VPC (The Swedish Central Securities Depository and Clearing Organisation) on April 22, 2003.

### **Purchase and sale of the Company's own shares**

The proposal to authorize the Board to decide on the purchase and sale of the Company's own shares was approved. In short this includes authority for the Board to decide on acquisitions of own shares over the stock exchange or by public offer as well as on sales in relation to business acquisitions.

For further information please contact:

Bengt Modéer, Senior Vice President, Corporate Communications, tel. +46-8-613 65 33, +46-70-513 65 33

Pia Irell, Investor Relations Director, Corporate Finance, tel. +46-8-613 65 91, +46-70-513 65 91

Kevin Smith, President Gambro Inc., Investor Relations US, tel. +1-303 231 4750

*Gambro is a global medical technology and healthcare company with leading positions in renal care - services and products - and blood component technology. Gambro Healthcare is one of the leading providers of kidney dialysis services in the world with more than 53,500 patients in 693 clinics worldwide. Gambro Renal Products comprises dialyzers, dialysis machines, blood lines and dialysis concentrates. Gambro BCT is the market leader in separation and handling of blood components. The group, with 2002 revenues of approximately SEK 27.6 billion (USD 2.7 billion), has 20,900 employees in some 40 countries.*

#### **Gambro AB**

A public company (publ)  
Reg no. 556041-8005  
Jakobsgatan 6, PO Box 7373  
SE-103 91 Stockholm  
Sweden  
Tel +46 8-613 65 00  
Fax +46 8-611 28 30  
info@gambro.com  
www.gambro.com